Archiv
Archiv anzeigen:
bis


Ibrutinib as Initial Therapy for Chronic Lymphocytic Leukemia

Michael E. Williams, MD, ScM reviewing Woyach JA et al. N Engl J Med 2018 Dec 1

Older patients with previously untreated disease had better outcomes with ibrutinib than with chemo-immunotherapy.


A New Complement Inhibitor for Paroxysmal Nocturnal Hemoglobinuria

David Green, MD, PhD reviewing Lee JW et al. Blood 2018 Dec 3, Kulasekararaj AG et al. Blood 2018 Dec 3

Ravulizumab was noninferior to eculizumab in both previously treated and treatment-naive patients.


CAR-T Cell Therapy for Diffuse Large B-Cell Lymphoma

Michael E. Williams, MD, ScM reviewing Schuster SJ et al. N Engl J Med 2018 Dec 1

Forty percent of patients with relapsed or refractory disease achieved complete remission.


Utility of Radical Prostatectomy for Localized Prostate Cancer

Robert Dreicer, MD, MS, MACP, FASCO reviewing Bill-Axelson A et al. N Engl J Med 2018 Dec 13

At 23 years of follow-up, life expectancy was nearly 3 years longer with prostatectomy than with watchful waiting.


Thromboprophylaxis with Apixaban for Cancer Patients

David Green, MD, PhD reviewing Carrier M et al. N Engl J Med 2018 Dec 4

Venous thromboembolism occurred less frequently with the direct oral anticoagulant apixaban than with placebo.


Risk for Esophageal Cancer in Patients with Gastroesophageal Reflux

David H. Ilson, MD, PhD reviewing Maret-Ouda J et al. JAMA Oncol 2018 Nov

Risk decreases over time with antireflux surgery or medication.


Counseling Individuals with Sickle Cell Trait

David Green, MD, PhD reviewing Pecker LH and Naik RP. Blood 2018 Nov 29

Recommendations for reproductive counseling and newborn screening


Reversing Red Cell Aplasia After Allogeneic Stem Cell Transplantation

Michael E. Williams, MD, ScM reviewing Chapuy CI et al. N Engl J Med 2018 Nov 8

Administration of the anti-CD38 monoclonal antibody daratumumab restored erythropoiesis.


Acute Myeloid Leukemia Relapse After Allogeneic Stem Cell Transplantation

Michael E. Williams, MD, ScM reviewing Christopher MJ et al. N Engl J Med 2018 Oct 31

The immune-mediated effects of the allograft on residual leukemia cells influenced the pattern of relapse.


A Guideline to Prevent Infection in Adults with Cancer-Related Immunosuppression

Daniel Kaul, MD reviewing Taplitz RA et al. J Clin Oncol 2018 Oct 20

An updated joint guideline from ASCO and IDSA on antimicrobial prophylaxis for patients with neutropenia


Archiv
Seite von 77
Editorial Member Board Empfehlungen

Prof. Dr. med. Beat Thürlimann

Brustzentrum St. Gallen
Kantonsspital St. Gallen

E-Mail: E-Mail anzeigen

Liebe Kolleginnen und Kollegen!

Im «New England Journal of Medicine» sind wieder einige interessante, auch «practice changing» Publikationen erschienen.

Kommentar weiterlesen

Enzalutamide for Castration-Resistant PSA-Only Prostate Cancer

Robert Dreicer, MD, MS, FACP, FASCO reviewing Hussain M et al. N Engl J Med 2018 Jun 28, Smith MR. N Engl J Med 2018 Jun 28

Metastasis-free survival was significantly improved with enzalutamide versus placebo.


First-Line Atezolizumab for Metastatic Nonsquamous NSCLC

Anne S. Tsao, MD reviewing Socinski MA et al. N Engl J Med 2018 Jun 14

Adding atezolizumab to bevacizumab and chemotherapy improved survival in chemotherapy-naive patients with non–small-cell lung cancer, regardless of EGFR or ALK mutation status.


Cytoreductive Nephrectomy for Metastatic Kidney Cancer

Robert Dreicer, MD, MS, FACP, FASCO reviewing Méjean A et al. N Engl J Med 2018 Jun 3, Motzer RJ and Russo P. N Engl J Med 2018 Jun 3

Adding nephrectomy to standard sunitinib therapy did not improve survival in patients with poor- and intermediate-risk disease.


ASCO 2018 Report — Breast Cancer

William J. Gradishar, MD

Highlights of the latest treatments


Intensive Surveillance for Colorectal Cancer

David H. Ilson, MD, PhD reviewing Wille-Jørgensen P et al. JAMA 2018 May 22, Sanoff HK. JAMA 2018 May 22

More- versus less-frequent testing did not improve survival after curative treatment for patients with stage II–III disease.


Fewer Patients with Breast Cancer Require Chemotherapy

William J. Gradishar, MD reviewing Sparano JA et al. N Engl J Med 2018 Jun 3

Outcomes were noninferior with endocrine therapy alone versus chemo-endocrine therapy in patients with intermediate recurrence scores.


Chemotherapy for Isolated Locoregional Recurrence of Breast Cancer

Henry Mark Kuerer, MD, PhD, FACS reviewing Wapnir IL et al. J Clin Oncol 2018 Apr 10

Long-term results confirm a benefit for ER-negative but not ER-positive patients.


Neoadjuvant Nivolumab for Resectable Lung Cancer

Anne S. Tsao, MD reviewing Forde PM et al. N Engl J Med 2018 Apr 16

A major pathological response was seen in 45% of patients.


First-Line Nivolumab plus Ipilimumab for Advanced Non–Small-Cell Lung Cancer

Anne S. Tsao, MD reviewing Hellmann MD et al. N Engl J Med 2018 Apr 16

Progression-free survival was improved versus chemotherapy for patients with high tumor mutation burden.


First-Line Lenvatinib vs. Sorafenib for Unresectable Hepatocellular Carcinoma

David H. Ilson, MD, PhD reviewing Kudo M et al. Lancet 2018 Feb 9, Reig M and Bruix J. Lancet 2018 Feb 9

Overall survival was noninferior and progression-free survival and response were superior with lenvatinib.